VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Ruff on Prior Bevacizumab in the VELOUR Trial

Paul Ruff, MD
Published: Friday, Oct 04, 2013

Paul Ruff, MD, director of medical oncology at the University of Witwatersrand, Johannesburg, South Africa, discusses the analysis of prior bevacizumab in the VELOUR trial in patients with metastatic colorectal cancer.

In the trial, about one-third of patients received prior bevacizumab. Bevacizumab is popular in the U.S., Ruff says, and is an anti-angiogenic therapy similar to aflibercept. Though the mechanism of action is different, aflibercept seems to be more potent than bevacizumab in the laboratory, but this has not been proven in the clinic.

In the trial, researchers wanted to see if patients who had received bevacizumab would benefit from aflibercept. Patients did see benefit, Ruff says, as the one-third part of the population who received prior bevacizumab did just as well as those who did not receive bevacizumab.

Paul Ruff, MD, director of medical oncology at the University of Witwatersrand, Johannesburg, South Africa, discusses the analysis of prior bevacizumab in the VELOUR trial in patients with metastatic colorectal cancer.

In the trial, about one-third of patients received prior bevacizumab. Bevacizumab is popular in the U.S., Ruff says, and is an anti-angiogenic therapy similar to aflibercept. Though the mechanism of action is different, aflibercept seems to be more potent than bevacizumab in the laboratory, but this has not been proven in the clinic.

In the trial, researchers wanted to see if patients who had received bevacizumab would benefit from aflibercept. Patients did see benefit, Ruff says, as the one-third part of the population who received prior bevacizumab did just as well as those who did not receive bevacizumab.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x